AVGR 0.78 Stock Price Avinger, Inc.
Range: | 0.703-5.45 | Vol Avg: | 230045 | Last Div: | 0 | Changes: | 0.04 |
Beta: | 1.16 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Fri Jan 30 2015 | Empoloyees: | 71 |
CUSIP: | 053734604 | CIK: | 0001506928 | ISIN: | US0537348775 | Country: | US |
CEO: | Mr. Himanshu N. Patel | Website: | https://avinger.com |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.